Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib
Sierra Oncology reported new analyses of Phase 3 clinical data highlighting the anemia related benefits of momelotinib directly compared to ruxolitinib, which were presented at the American Society of Hematology Annual Meeting. The new analyses demonstrate that: Patients who received momelotinib had "significantly decreased" transfusion requirements compared to those treated with ruxolitinib, including a nearly 10-fold higher odds of receiving no transfusions during the 24-week study period, the company said, Patients receiving momelotinib had a "significantly reduced" chance of receiving one transfusion, it added. "Transfusion dependency and moderate to severe anemia are the most important negative prognostic factors for overall survival in myelofibrosis," said Dr. Ruben Mesa, Director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. "These novel analyses of RBC transfusion data from the Phase 3 SIMPLIFY-1 study further demonstrate momelotinib's compelling anemia benefits, including a substantively reduced transfusion burden compared directly with ruxolitinib, and further support momelotinib as a potentially desirable treatment option for patients with myelofibrosis."